Biovica has recruited Wing Cheng as Market Access & QA Director. He will join Biovica on the 8th of October 2018. Wing has extensive experience in the regulatory and reimbursement area from different companies, national and international authorities.
Below is a summary of the decisions taken at the Annual General Meeting, AGM. The Meeting resolved that available funds of SEK 60,768,811 will be carried forward. The Meeting resolved that Board members should be compensated with SEK 125,000 for Directors and SEK 200,000 for the Chairman of the Board. The Meeting also resolved that [...]
Biovica International AB (publ) today announced that the company received positive feedback from the FDA for the next step in the regulatory approval process. The feedback from the FDA ensures that the analytical validation is conducted in a manner that meets the FDA's requirements, so the product can get 510(k) clearance.
Biovica International AB (publ) have received a new patent in Japan. The patent refers to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The new patent is valid until 13th of May 2031. With this patent, Biovica has received patent protection for the PCR-based product on all 16 markets the company has applied for patent protection.
Biovica International AB (publ) have agreed to collaborate with WntResearch AB regarding a biomarker for Foxy-5 treatment. The objective of the research is to deliver a companion diagnostic, a biomarker, coupled with Foxy-5.
Biovica will present at Småbolagsdagen, a small-cap investor conference, held in Stockholm on June 11 at hotel Sheraton Stockholm. The event is arranged by Aktiespararna and the company will be represented by CEO Anders Rylander.
DiviTum results from a large AstraZeneca study are presented today at the ASCO meeting in Chicago, the largest cancer congress in the world. The study, including 244 women with metastatic breast cancer demonstrates DiviTum’s ability to provide precise prognosis and evaluation of therapy effect for better patient outcome, from a blood sample.
New study results presented at ASCO supports DiviTum® for monitoring advanced breast cancer treatment
The EFECT-study evaluated standard hormonal therapies for women with advanced breast cancer and DiviTum® was used as a non-invasive tool for monitoring therapy response. 244 patients had blood samples analyzed with DiviTum® in a collaboration between AstraZeneca, Prato Hospital, Italy, Institute Jules Bordet, Belgium, British Columbia Cancer Agency, Canada and Biovica, Sweden.
Biovica announces the appointment of Pontus Nobréus as Business Development Director, effective end of May 2018. Mr Nobréus has over 20 years’ experience working within the global sales, commercial and business development roles. Most recently, he was Global Sales Manager at Euro Diagnostica.
Biovica takes the next step in the process of commercializing DiviTum by launching a subsidiary in the United States.